• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Review  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

I. Review of Epidemiological and Preclinical Studies

Nina E. Shepardson, MS; Ganesh M. Shankar, MD, PhD; Dennis J. Selkoe, MD

Arch Neurol. 2011;68(10):1239-1244. doi:10.1001/archneurol.2011.203

During the last 2 decades, evidence has accumulated that a high cholesterol level may increase the risk of developing Alzheimer disease (AD). With the global use of statins to treat hypercholesterolemia, this finding has led to the anticipation that statins could prove useful in treating or preventing AD. However, the results of work on this topic are inconsistent: some studies find beneficial effects, but other studies do not. In this first segment of a 2-part review, we examine the complex preclinical and clinical literature on cholesterol level and AD. First, we review epidemiological research on cholesterol level and the risk of AD and discuss the relevance of discrepancies among studies with regard to participants' age and clinical status. Second, we assess studies correlating cholesterol level with neuropathological AD type. The potential molecular mechanisms for the apparent adverse effects of cholesterol on the development of AD are then discussed. Third, we review preclinical studies of statin use and AD. Therefore, this first part of our review provides the background and rationale for investigating statins as potential therapeutic agents in patients with AD, the subject of the second part.

Author Affiliations: Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School (Ms Shepardson and Drs Shankar and Selkoe), and Department of Neurological Surgery, Massachusetts General Hospital (Dr Shankar), Boston, Massachusetts.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cholesterol Level and Statin Use in Alzheimer Disease: II. Review of Human Trials and Recommendations
Shepardson et al.
Arch Neurol 2011;68:1385-1392.
ABSTRACT | FULL TEXT